Sign Up Today and Learn More About Immunai Stock
Invest in or calculate the value of your shares in Immunai or other pre-IPO companies through EquityZen's platform.
Immunai Stock (IMMA)
Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.
About Immunai Stock
Founded
2018
Headquarters
New York, NY, US
Industries
Software, Artificial Intelligence, Financial Services
Immunai Press Mentions
Stay in the know about the latest news on Immunai
mRNA Vaccine & Therapeutics Market to Reach $850.9M by 2033, Driven by AI & Oncology Breakthroughs | DataM Intelligence
einpresswire • Jun 22, 2025
Immunai to Feed AI Models With Single-Cell Data Generated From Parker Institute Pan-Cancer Cohort
genomeweb • Jun 21, 2025
AstraZeneca Racks Up AI Partners, Seeking To Stop Cancer at All Stages
biospace • Jun 02, 2025
Systems, software, and methods for multiomic single cell classification and …
patents • May 04, 2025
Immunai and Parker Institute to Build Massive Cancer Single-Cell Dataset
genengnews • Apr 26, 2025
Immunai Management
Leadership team at Immunai
Chief Technology Officer and Co-founder
Luis F Voloch
Scientific Co-founder
Danny Wells
Join now and verify your accreditation status to gain access to:
- Immunai Current Valuation
- Immunai Stock Price
- Immunai Management
- Available deals in Immunai and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Immunai Cap Table and Funding History by Share Class and Liquidity Preferences
- Immunai Revenue and Financials
- Immunai Highlights
- Immunai Business Model
- Immunai Risk Factors
- Immunai Research Report from SACRA Research
Trading Immunai Stock
How to invest in Immunai stock?
Accredited investors can buy pre-IPO stock in companies like Immunai through EquityZen funds. These investments are made available by existing Immunai shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Immunai stock?
Shareholders can sell their Immunai stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
